Clinical trial
A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (ILLUMINATE-C)
A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (ILLUMINATE-C)
ClinicalTrials.gov ID: NCT04152200
Sponsor: Alnylam Pharmaceuticals
Information provided by: Alnylam Pharmaceuticals (Responsible Party)
Last Update Posted: 2024-05-13
Brief Summary:
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in patients with Advanced Primary Hyperoxaluria Type 1 (PH1).
Official Title:
ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1)
Intervention / Treatment:
- Drug: Lumasiran
| Category | Value |
|---|---|
| Study Start (Actual) |
2020-01-21
|
| Primary Completion (Actual) |
2021-05-18
|
| Study Completion (Estimated) |
2025-07
|
| Enrollment (Actual) | 21 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
ALN-GO1-005
2019-001346-17 (EudraCT Number) 2023-503382-29-00 (EU Trial (CTIS) Number) |